Intravenous administration of stabilized antisense lipid particles (SALP) leads to activation and expansion of liver natural killer cells

Antisense and Nucleic Acid Drug Development

Volumn 10, Issue 3, 2000, Pages 217-224

  Bramson, Jonathan L ^a   Bodner, Carolyn A ^b   Johnson, Janet ^b   Semple, Sean ^b   Hope, Michael J ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b Inex Pharmaceuticals   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM DERIVATIVE; CHOLESTEROL; GLYCEROPHOSPHORYLCHOLINE; LIPID; OLIGONUCLEOTIDE; SPHINGOSINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DRUG DELIVERY SYSTEM; IMMUNOSTIMULATION; LIVER; MITOGENESIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0033913973     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.2000.10.217     Document Type: Article

References (31)

1. BOGGS, R.T., McGRAW, K., CONDON, T., FLOURNOY, S., VILLIET, P., BENNETT, C.F., and MONIA, B.P. (1977). Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev. 7, 461-467.
2. BRAMSON, J., HITT, M., GALLICHAN, W.S., ROSENTHAL, K.L., GAULDIE, J., and GRAHAM, F.L. (1996). Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: In vitro and in vivo production of biologically active interleukin-12. Hum. Gene Ther. 7, 333-342.
3. BROSSAY, L., CHIODA, M., BURDIN, N., KOEZUKA, Y., CASORATI, G., DELLABONA, P., and KRONENBERG, M. (1998). CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 188, 1521-1528.
4. CHEN, H., HUA, H., and PAUL, W.E. (1997). NK1.1 + CD4+ T cells lose NK1.1 expression upon in vitro activation. J. Immunol. 158, 5112-5119.
5. CHONN, A., and CULLIS, P.R. (1995). Recent advances in liposomal drug-delivery systems. Curr. Opin. Biotechnol. 6, 698-708.
6. CHU, R.S., TAGONI, O.S., KRIEG, A.M., LEHMANN, P.V., and HARDING C.V. (1997). CpG oligodeoxynucleotides act as adjuvants that switch on T helper (Th1) immunity. J. Exp. Med. 186, 1623-1631.
7. CITRO, G., D'AGNANO, I., LEONETTI, C., PERINI, R., BUCCI, B., ZON, G., CALABRETTA, B., and ZUPI, G. (1998). C-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res. 58, 283-289.
8. CROOKE, S.T. (1998). An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev. 8, 115-122.
9. CUL, J., SHIN, T., KAWANO, T., SATO, H., KONDO, E., TOURA, I., KANEKO, Y., KOSEKI, H., KANNO, M., and TANIGUCHI, M. (1997). Requirement for Vα14 KNT cells in IL-12-mediated rejection of tumors. Science 278, 1623-1626.
10. DAVIS, H.L., WEERANTA, R., WALDSCHMIDT, T.J., TYGRETT, L., SCHORR, J., and KRIEG, A.M. (1998). CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160, 870-876.
11. ELKINS, K.L., RHINEHART-JONES, T.R., STIBITZ, S., CONOVER, J.S., and KLINMAN, D.M. (1999). Bacterial DNA con- taining CpO motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162, 2291-2298.
12. GOKHALE, P.C., SOLDATENKOV, V., WANG, F.H., RAHMAN, A., DRITSCHILO, A., and KASID, U. (1997). Antisense raf oligodeoxynucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: Implication for gene therapy of radioresistant cancer. Gene Ther. 4, 1289-1299.
13. KAWANO, T., GUI, J., KOEZUKA, Y., TOURA, I., KANEKO, Y., SATO, H., KONDA, E., HARADA, M., KOSEKI, H., NAKAYAMA, T., TANAKA, Y., and TANIGUCHI, M. (1998). Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα 14 NKT cells. Proc. Natl. Acad. Sci. USA 95, 5690-5693.
14. KLIMUK, S.K., SEMPLE, S.C., NAHIRNEY, P.N., MULLEN, M.C., BENNETT, C.F., SCHERRER, P., and HOPE, M.J. (2000). Enhanced anti-inflammatory activity of a liposomal ICAM-1 antisense oligonucleotide in an acute model of contact hypersensitivity. J. Pharmacol. Exp. Ther. 292, 480-488.
15. KLIMUK, S.K., SEMPLE, S.C., SCHERRER, P., and HOPE, M.J. (1999). Contact hypersensitivity: A simple model for the characterization of disease-site targeting by liposomes. Biochem. Biophys. Acta 1417, 191-201.
16. KREN, B.T., BANDYOPADHYAY, P., and STEER, C.J. (1998). In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides. Nat. Med. 4, 285-290.
17. KRIEG, A.M. (1996). Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 4, 73-76.
18. KRIEG, A.M., LOVE-HOMA, L., YI, A.-K., and HARTY, J.T. (1998a). CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 161, 2428-2434.
19. KRIEG, A.M., WU, T., WEERATNA, R., EFLER, S.M., LOVEHOMAN, L., YANG, L., YI, A.-K., SHORT, D., and DAVIS, H.L. (1998b). Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. USA 95, 12631-12636.
20. LEONETTI, C., D'AGNANO, I., LOZUPONE, F., VALENTINI, A., GEISER, T., ZON, G. CALABRETTA, B., CITRO, G., and ZUPI, G. (1996). Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J. Natl. Cancer Inst. 88, 419-422.
21. MATZINGER, P. (1998). An innate sense of danger. Semin. Immunol. 10, 399-415.
22. MONTEITH, D.K., HENRY, S.P., HOWARD, R.B., FLOURNOY, S., LEVIN, A.A., BENNET, C.F., and CROOKE, S.T. (1997). Immune stimulation - A class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des. 12, 421-432.
23. NECKERS, L.M., KANEKAL, M., and CONNELL, Y. (1998). Non-antisense oligonucleotide approaches for experimental treatment of glioblastoma. Antisense Nucleic Acid Drug Dev. 8, 177-179.
24. SEMPLE, S.C., KLIMUK, S.K., HARASYM, T.O., DOS SANTOS, N., SANDHU, A., ANSELL, S.M., SCHERRER, P., and HOPE, M.J. (2000a). Stabilized antisense-lipid particles for systemic applications: Generation, characterization and in vivo activity. Methods Enzymol. 313, 322-341.
25. SEMPLE, S.C., KLIMUK, S.K., HARASYM, T.O., and HOPE, M.J. (2000b). Lipid-based formulations of antisense oligonucleotides for systemic delivery applications. Methods Enzymol. In press.
26. SMITH, J.B., and WICKSTROM, E. (1998). Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model. J. Natl. Cancer Inst. 90, 1146-1154.
27. SUZUKI, K., MORI, A., ISHII, K.J., SAITO, J., SINGER, D.H., KLINMAN, D.M., KRAUSE, P.R., and KOHN, L.D. (1999). Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. Proc. Natl. Acad. Sci. USA 96, 2285-2290.
28. VAISH, N.K., KORE, A.R., and ECKSTEIN, F. (1998). Recent developments in the hammerhead ribozyme field. Nucleic Acids Res. 26, 5237-5242.
29. WEBB, M.S., KLIMUK, S.K., SEMPLE, S.C., and HOPE, M.J. (1998). Lipid-based carriers for the systemic delivery of antisense drugs. In: Manual of Antisene Methodology. G. Hartmann, and S. Endres, eds. (Kluwer Academic Publishers, Boston), pp. 167-190.
30. WOOLF, T.M. (1998). Therapeutic repair of mutated nucleic acid sequences. Nat. Biotechnol. 16, 341-344.
31. ZIMMERMAN, S., EGETER, O., HAUSMANN, S., LIPFORD, G.B., ROCKEN, M., WAGNER, H., and HEEG, K. (1998). CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 160, 3627-3630.